학술논문

Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers
Document Type
article
Source
Retrovirology. 14(1)
Subject
Microbiology
Biological Sciences
Clinical Research
Biotechnology
Infectious Diseases
Sexually Transmitted Infections
HIV/AIDS
Infection
Good Health and Well Being
Capsid Proteins
Cells
Cultured
Endogenous Retroviruses
Epitopes
Gene Products
gag
HIV Antibodies
HIV Infections
HIV-1
Humans
Peptide Fragments
Recombinant Proteins
Viral Proteins
HIV
HERV-K
Antibodies
Gag
Elite Controllers
Viremic non-controllers
Clinical Sciences
Virology
Language
Abstract
BackgroundHuman endogenous retroviruses (HERVs) comprise approximately 8% of the human genome and while the majority are transcriptionally silent, the most recently integrated HERV, HERV-K (HML-2), remains active. During HIV infection, HERV-K (HML-2) specific mRNA transcripts and viral proteins can be detected. In this study, we aimed to understand the antibody response against HERV-K (HML-2) Gag in the context of HIV-1 infection.ResultsWe developed an ELISA assay using either recombinant protein or 164 redundant "15mer" HERV-K (HML-2) Gag peptides to test sera for antibody reactivity. We identified a total of eight potential HERV-K (HML-2) Gag immunogenic domains: two on the matrix (peptides 16 and 31), one on p15 (peptide 85), three on the capsid (peptides 81, 97 and 117), one on the nucleocapsid (peptide 137) and one on the QP1 protein (peptide 157). Four epitopes (peptides 16, 31, 85 and 137) were highly immunogenic. No significant differences in antibody responses were found between HIV infected participants (n = 40) and uninfected donors (n = 40) for 6 out of the 8 epitopes tested. The antibody response against nucleocapsid (peptide 137) was significantly lower (p